[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-426605-105":59,"doc-detail-426605-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","klf13-restrains-dll4-muscular-notch2-axis-to-improve-sarcopenia","KLF13 RESTRAINS DLL4-MUSCULAR NOTCH2 AXIS - TO IMPROVE SARCOPENIA","","Krüppel-like factor 13 (KLF13) is highly expressed in skeletal muscle and regulates cellular energy metabolism, with suspected roles in sarcopenia. In a dexamethasone-induced muscle atrophy mouse model, KLF13 knockout reduced muscle strength, muscle weight, and exhaustive running distance. KLF13 overexpression preserved muscle mass and performance in vivo, while clofoctol protected against atrophy. Mechanistically, KLF13 suppresses Dll4, inhibiting the Dll4-Notch2 axis, and dexamethasone blocks KLF13 transcription and promotes KLF13 ubiquitination. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/klf13-restrains-dll4-muscular-notch2-axis-to-improve-sarcopenia/426605/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/klf13-restrains-dll4-muscular-notch2-axis-to-improve-sarcopenia/426605.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What happens to muscle function when KLF13 is knocked out in the dexamethasone mouse model?","Question",{"text":112,"@type":113},"Compared with controls, the KLF13 knockout group shows decreased overall muscle strength, reduced muscle weight for major muscles, and a shorter exhaustive running distance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does KLF13 overexpression affect muscle atrophy in vivo?",{"text":117,"@type":113},"KLF13 overexpression preserves muscle mass and improves exhaustive running distance in a diabetes-induced skeletal muscle atrophy model.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links KLF13 to prevention of muscle atrophy?",{"text":121,"@type":113},"Transcriptome and luciferase assays identify Dll4 as a target of KLF13; KLF13 suppresses Dll4 expression, inhibiting the Dll4-Notch2 axis and preventing atrophy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},426605,1791155206,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","378 Innovation in Aging, 2025, Vol. 9, No. S2  \nAbstract citation ID: igaf122.1283  \nKLF13 RESTRAINS DLL4-MUSCULAR NOTCH2 AXIS  \nTO IMPROVE SARCOPENIA  \nZhen Liang, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People’s Republic)  \nKrüppel-like factor 13 (KLF13), a central regulator of cellular energy metabolism, is highly expressed in skeletal muscle and implicated in the pathogenesis of several diseases. This study investigated the role ofKLF13 in sarcopenia.In a dexamethasone-induced muscle atrophy mouse model, compared to the control group, the KLF13 knockout group had decreased overall muscle strength (1.77 ± 0.10 vs. 1.48 ± 0.16, P \u003C0.01), muscle weight (%) 76.0 ±  \n5.69 vs. 60.7 ± 7.23, P \u003C0.001 for gastrocnemius (Gas) and 75.8 ± 6.21 vs. 67.5 ± 5.01, P \u003C0.05] for tibialis anterior, and exhaustive running distance (m) (495.5 ± 64.8 vs. 315.5 ± 60.9, P \u003C 0.05) .  \nKLF13 overexpression preserved muscle mass (Gas: 100 ± 6.38 vs. 120 ± 14.4, P \u003C0.01) and exhaustive running distance (423.8 ± 59.04 vs. 530.2 ± 77.45, P \u003C0.05) in an in vivo diabetes-induced skeletal muscle atrophy model. Clofoctol protected against dexamethasone-induced muscle atrophy. Myotubes treated with dexamethasone were aggravated by KLF13 knockout, but anti-atrophic effects were achieved by inducing KLF13 overexpression. Transcriptome analyses and luciferase reporter assays demonstrate that delta-like 4 (Dll4) was a novel target gene of KLF13. KLF13 suppressed Dll4 expression, leading to the inhibition of the Dll4-Notch2 axis and prevention of muscle atrophy.  \nDexamethasone inhibited KLF13 expression by inhibiting myogenic differentiation 1-mediated KLF13 transcriptional activation and promoting F-Box and WD repeat domain containing 7-mediated KLF13 ubiquitination. These findings provide novel insights into mechanisms underlying skeletal muscle atrophy and sarcopenia with potential therapeutic targets.","cbCaiqtBekW25ync","https://ap.wps.com/l/cbCaiqtBekW25ync","pdf",375330,"English","# Abstract\n## Study models and phenotypes\n## Molecular mechanism: KLF13-Dll4-Notch2 axis","[{\"question\":\"What happens to muscle function when KLF13 is knocked out in the dexamethasone mouse model?\",\"answer\":\"Compared with controls, the KLF13 knockout group shows decreased overall muscle strength, reduced muscle weight for major muscles, and a shorter exhaustive running distance.\"},{\"question\":\"How does KLF13 overexpression affect muscle atrophy in vivo?\",\"answer\":\"KLF13 overexpression preserves muscle mass and improves exhaustive running distance in a diabetes-induced skeletal muscle atrophy model.\"},{\"question\":\"What mechanism links KLF13 to prevention of muscle atrophy?\",\"answer\":\"Transcriptome and luciferase assays identify Dll4 as a target of KLF13; KLF13 suppresses Dll4 expression, inhibiting the Dll4-Notch2 axis and preventing atrophy.\"}]","KLF13 RESTRAINS DLL4-MUSCULAR NOTCH2 AXIS - TO IMPROVE SARCOPENIA | PDF",1790641103]